Ulcerative Proctitis:
Significant Disease...

At the time of UC diagnosis, 33% to 50% of patients have disease limited to the rectum (ie, ulcerative proctitis [UP])1-3

  • Up to 50% of patients diagnosed with flaring UP will eventually develop more extensive inflammation2
  • In one study, about a third of patients with UP progressed to pancolitis2

5-ASA (mesalamine) suppositories are recommended by practice guidelines and preferred by patients4

  • ACG and Crohn’s & Colitis Foundation of America (CCFA) guidelines recommend suppositories as a first-line therapy for flaring UP4
  • For patients with worsening UP symptoms, over 90% were willing to take a suppository without hesitation compared with just over 50% for an enema, according to a patient survey (N=250)5

Mesalamine suppositories reach up to the first 15 to 20 cm (average disease boundary) of the rectum4

More than 90% of the liquid in 5-ASA enemas tends to bypass the rectum6



Information on this website is not intended to replace the advice of your physician(s). Please consider what you learn here a starting point for a conversation with your physician. All care of ulcerative proctitis and related conditions must be guided by the appropriate healthcare professional. CANASA® is a prescription drug.

References
1.Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalazine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95(7):1749-1754. 2.Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38(6):1137-1146. 3.D’Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. Am J Gastroenterol. 1998;93:799-803. 4.Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006;12(10):972-978. 5.Taenzler 2009: 2-16 Ulcerative Proctitis Patient's Preference for Topical Formulations of Mesalamine Administration. 6.Van Bodegraven AA, Boer RO, Lourens J, Tuynman HARE, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Ailment Pharmacol Ther. 1996;10:327-332.

 

CANASA® is available by prescription only.

CANASA® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.

CANASA® is contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated fatty acid esters (Hard Fat, NF)], or to salicylates (including Aspirin).

As with other mesalamine containing products, less common but possibly serious side effects such as acute intolerance syndrome, pericarditis and pancolitis may occur.

Patients on CANASA® 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.

Caution should be exercised when CANASA® suppositories are initially used in patients known to be allergic to sulfasalazine.

CANASA® was generally well tolerated in clinical studies. The most common side effects of CANASA® are dizziness (3%), rectal pain (1.8%), fever (1.2%), rash (1.2%), acne (1.2%), and colitis (1.2%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.